Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AMRX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| CREXONT ER | Parkinson Disease | Phase 4 · NCT06765668 | Recruiting |
| Albuterol | Asthma | Phase 3 · NCT03549897 | Unknown |
| Voltaren Topical Gel, 1% | Osteoarthritis | Phase 3 · NCT02121002 | Completed |
| Testosterone Topical Gel, 1.62% Metered Pump | Primary Hypogonadism | Phase 3 · NCT02110368 | Completed |
| Test Product | Asthma | Phase 3 · NCT03562949 | Terminated |
| Test - Bimatoprost 0.01% Ophthalmic Solution | Glaucoma, Open-Angle | Phase 3 · NCT05401357 | Recruiting |
| Beclomethasone Dipropionate | Asthma | Phase 3 · NCT03562949 | Terminated |
| Reference - LUMIGAN® (Bimatoprost 0.01%… | Glaucoma, Open-Angle | Phase 3 · NCT05401357 | Recruiting |
| Phenazopyridine Hydrochloride Tables, USP 200 mg | Uncomplicated Urinary Tract Infections | Phase 3 · NCT01650051 | Completed |
| Nasonex Nasal Spray, 50 mcg | Seasonal Allergic Rhinitis | Phase 3 · NCT02125253 | Completed |
| Mometasone Furoate Nasal Spray, 50 mcg | Seasonal Allergic Rhinitis | Phase 3 · NCT02125253 | Completed |
| Asenapine Sublingual Tablets 10 mg | Schizophrenia | Phase 2/3 · NCT02072954 | Completed |
| AndroGel (testosterone gel) 1.62% Metered-Dose… | Primary Hypogonadism | Phase 3 · NCT02110368 | Completed |
| LUMIGAN® (bimatoprost ophthalmic solution) 0.01% | Open-angle Glaucoma | Phase 1 · NCT06267274 | Unknown |
| KSHN001126 150mg | Healthy Postmenopausal Women | Phase 1 · NCT06467201 | Completed |
| Bimatoprost Ophthalmic Solution, 0.01% | Open-angle Glaucoma | Phase 1 · NCT06267274 | Unknown |
Also used in these trials (approved or third-party drugs, not AMRX's own candidates): Testosterone Cypionate, Phenazopyridine Hydrochloride, Imatinib Mesylate, Estradiol, Diclofenac Sodium Topical Gel, 1%, Methotrexate Sodium.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AMRX holds $157.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 7 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AMRX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Tushar Bhikhubhai Patel 10% owner |
Insider | 61,341,678 | 17.61% | 2026-08-10 |
| Tushar Patel | 5%+ holder (13D) | 61,341,678 | 17.61% | 2026-08-10 |
| Chintu Patel Co-CEO, Director · +185,185 options |
Insider | 32,523,507 | 9.33% | 2026-08-10 |
| Chirag Patel | 5%+ holder (13D) | 29,097,645 | 8.35% | 2026-08-10 |
| Chirag K. Patel President & Co-CEO, Director · +185,185 options |
Insider | 29,044,624 | 8.34% | 2026-08-10 |
| BlackRock, Inc. | Institution (13G, 5%+) | 24,121,119 | 6.92% | 2026-03-31 |
| Patel Dipan | 5%+ holder (13D) | 16,904,263 | 4.85% | 2025-12-31 |
| Gautam Patel Director · +19,824 options |
Insider | 1,927,595 | 0.55% | 2026-08-10 |
| Paul M Meister Director · +30,837 options |
Insider | 832,800 | 0.24% | 2026-05-06 |
| Tasos Konidaris Executive Vice President & CFO · +87,963 options |
Insider | 449,434 | 0.13% | 2026-03-03 |
| Jeffrey P. George Director · +19,824 options |
Insider | 344,614 | 0.10% | 2026-05-06 |
| Ted C Nark Director · +19,824 options |
Insider | 325,848 | 0.09% | 2026-05-06 |
Share count 348,412,726 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AMRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →